Get started
Author

Meghan C. Baronet

Observed names: M. Baronet, Meghan C Baronet
OpenAlex ID: A5116311318
Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study.
2025 · Aaron Richard Hansen, David A. Pattison, et al. · Journal of Clinical Oncology · 5
PDF
2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial
2025 · A.R. Hansen, D.A. Pattison, et al. · Annals of Oncology · 2
TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212 Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation–Resistant Prostate Cancer
2026 · Aaron R. Hansen, David A. Pattison, et al. · Journal of Nuclear Medicine
PDF
Phase 2 expansion study of 212 Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial.
2026 · Aaron Richard Hansen, Jeffrey C. Goh, et al. · Journal of Clinical Oncology
Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and novel 212Pb PET Clinical Imaging
2026 · Aaron R Hansen, Stanley Ngai, et al. · Journal of medical imaging and radiation sciences
Works count: 5
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type